Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
- PMID: 20819842
- PMCID: PMC3057423
- DOI: 10.1177/0333102410379890
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Abstract
Objective: The purpose of this study was to assess psychometric properties of the six-item Headache Impact Text (HIT-6™) across episodic and chronic migraine.
Methods: Using a migraine screener and number of headache days per month (HDPM), participants from the National Survey of Headache Impact (NSHI) study and the HIT-6 validation study (HIT6-V) were selected for this study. Eligible participants were categorized into three groups: chronic migraine (CM: ≥ 15 HDPM); episodic migraine (EM: < 15 HDPM); non-migraine headaches. Reliability and validity of the HIT-6 were evaluated.
Results: A total of 2,049 survey participants met the inclusion/exclusion criteria for this study. Participants were identified as 6.4% CM; 42.1% EM; 51.5% non-migraine, with respective mean HIT-6 scores: 62.5 ± 7.8; 60.2 ± 6.8; and 49.1 ± 8.7. High reliability was demonstrated with internal consistency (time1/time2) of 0.83/0.87 in NSHI, and 0.82/0.92 in HIT6-V. Intra-class correlation for test-retest reliability was very good at 0.77. HIT-6 scores correlated significantly (p < .0001) with total Migraine Disability Assessment Scale scores (r = 0.56), headache pain severity (r = 0.46), and HDPM (r = 0.29). Discriminant validity analysis showed significantly different HIT-6 scores (F = 488.02, p < .0001) across the groups.
Conclusion: Results from these analyses confirm that the HIT-6 is a reliable and valid tool for discriminating headache impact across episodic and chronic migraine.
Similar articles
-
Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review.Headache. 2020 Jan;60(1):28-39. doi: 10.1111/head.13701. Epub 2019 Dec 6. Headache. 2020. PMID: 31811654 Free PMC article. Review.
-
Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine.Headache. 2019 May;59(5):756-774. doi: 10.1111/head.13497. Epub 2019 Mar 12. Headache. 2019. PMID: 30861580 Free PMC article. Clinical Trial.
-
Botulinum toxins for the prevention of migraine in adults.Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD011616. doi: 10.1002/14651858.CD011616.pub2. Cochrane Database Syst Rev. 2018. PMID: 29939406 Free PMC article. Review.
-
Reliability and Validity of the Persian HIT-6 Questionnaire in Migraine and Tension-type Headache.Pain Pract. 2014 Sep;14(7):625-31. doi: 10.1111/papr.12120. Epub 2013 Nov 18. Pain Pract. 2014. PMID: 24237583
-
Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.Headache. 2012 Mar;52(3):409-21. doi: 10.1111/j.1526-4610.2011.01997.x. Epub 2011 Sep 19. Headache. 2012. PMID: 21929662
Cited by
-
Headache in Patients with Sellar Disease: Clinicomorphological Predictors of Headache and the Outcome of Endoscopic Transsphenoidal Surgery.J Neurol Surg B Skull Base. 2023 Mar 20;85(3):247-254. doi: 10.1055/a-2036-0652. eCollection 2024 Jun. J Neurol Surg B Skull Base. 2023. PMID: 38721359 Free PMC article.
-
Manual cervical therapy and vestibular migraine: A case series.Health Open Res. 2023 Aug 22;5:12. doi: 10.12688/healthopenres.13319.3. eCollection 2023. Health Open Res. 2023. PMID: 38708034 Free PMC article.
-
Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.Toxins (Basel). 2024 Apr 7;16(4):178. doi: 10.3390/toxins16040178. Toxins (Basel). 2024. PMID: 38668603 Free PMC article.
-
Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization.J Headache Pain. 2024 Apr 18;25(1):58. doi: 10.1186/s10194-024-01772-9. J Headache Pain. 2024. PMID: 38637736 Free PMC article.
-
Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study.Pain Ther. 2024 Jun;13(3):557-576. doi: 10.1007/s40122-024-00586-6. Epub 2024 Mar 28. Pain Ther. 2024. PMID: 38546937 Free PMC article.
References
-
- Rasmussen BK. Epidemiology of migraine. Biomed Pharmacother 1995; 49: 452–455 - PubMed
-
- Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343–349 - PubMed
-
- Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003; 43: 336–342 - PubMed
-
- Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 2003; 23: 441–450 - PubMed
-
- Monzon MJ, Lainez MJ. Quality of life in migraine and chronic daily headache patients. Cephalalgia 1998; 18: 638–643 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous